Procept Biorobotics Corp
NASDAQ:PRCT
Procept Biorobotics Corp
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods.
Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods.
Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
Revenue Growth: PROCEPT BioRobotics reported Q4 2025 revenue of $76.4 million, up 12% year-over-year, but noted revenue was lower than anticipated due to business practice changes.
Procedure Volume: Q4 U.S. procedures reached 12,200, representing about 69% growth year-over-year, with management emphasizing strong underlying demand.
Guidance Reset: 2026 revenue guidance was reset lower to $390–410 million, reflecting 27–33% annual growth, mainly due to ending bulk handpiece discounts and aligning handpiece sales to actual procedure volumes.
Margin Pressure: Q4 gross margin fell to 60.6% from 64% a year ago, impacted by lower consumable revenue and a one-time field action.
Pricing Discipline: The company eliminated bulk handpiece discounts, resulting in a 5% sequential increase in average selling price to $3,340.
Strategic Reorg: A new commercial structure was implemented, including a dedicated launch team and regional realignment, expected to cause short-term disruption but support long-term growth.
Profitability Path: Management expects positive EBITDA in Q4 of 2026 and remains confident in the long-term growth and profitability trajectory.
